Evolution to AML and MDS According to Cytoreductive Agents Received in 357 ET Patients
| Agent . | No. of ET Patients Treated . | Cases of AML or MDS . |
|---|---|---|
| No. (%) . | ||
| 32P | ||
| Alone | 29 | 2 (7) |
| And other agents* | 11 | 1 (9) |
| Total | 40 | 3 (7.5) |
| Busulfan | ||
| Alone | 35 | 1 (3) |
| And other agents* | 6 | 1 (17) |
| Total | 41 | 2 (5) |
| HU | ||
| Alone | 201 | 7 (3.5) |
| And other agents† | 50 | 7 (14) |
| Total | 251 | 14 (5.5) |
| Pipobroman | ||
| Alone | 12 | 0 (0) |
| And other agents* | 31 | 5 (16) |
| Total | 43 | 5 (12) |
| Untreated | 31 | 0 (0) |
| Agent . | No. of ET Patients Treated . | Cases of AML or MDS . |
|---|---|---|
| No. (%) . | ||
| 32P | ||
| Alone | 29 | 2 (7) |
| And other agents* | 11 | 1 (9) |
| Total | 40 | 3 (7.5) |
| Busulfan | ||
| Alone | 35 | 1 (3) |
| And other agents* | 6 | 1 (17) |
| Total | 41 | 2 (5) |
| HU | ||
| Alone | 201 | 7 (3.5) |
| And other agents† | 50 | 7 (14) |
| Total | 251 | 14 (5.5) |
| Pipobroman | ||
| Alone | 12 | 0 (0) |
| And other agents* | 31 | 5 (16) |
| Total | 43 | 5 (12) |
| Untreated | 31 | 0 (0) |
*Generally HU.
Generally pipobroman.